Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Launch of Sanofi and GSK COVID-19 vaccine could be delayed until late 2021

By Brian Buntz | December 11, 2020

Sanofi (NYSE:SNY) and Glaxo Smith Kline’s (NYSE:GSK) have confirmed a delay in their adjuvanted recombinant protein-based COVID-19 vaccine owing to an inadequate immune response in older adults in a Phase 1/2 trial. 

Sanofi and GSK now plan to launch a Phase 2b study in February 2021 to investigate a new vaccine formulation. 

If that study reaches primary endpoints, the companies could launch an international Phase 3 study in the second quarter of 2021 and regulatory submissions in the second half of the year.  

Sanofi and GSK had planned on launching a Phase 3 trial by the end of 2020. 

According to their revised timetable, the companies anticipate that the resulting vaccine would be available in the fourth quarter of 2021. By that point, vaccines would likely be available from Pfizer (NYSE:PFE) and its partner BioNTech, Moderna (NSDQ:MRNA), Janssen (NYSE:JNJ) and AstraZeneca (LON:AZN). 

Sanofi’s and GSK’s initial Phase 1/2 did show some promise for younger adults. According to an interim analysis, adults aged 18 to 49 developed a similar immune response to patients who had recovered from COVID-19. Adults 50 and over, however, did not 

The companies note their vaccine could be improved using a new antigen formulation that demonstrated efficacy against SARS-CoV-2 in non-human primates. In particular, the modified formulation guarded against COVID-19 pulmonary pathology and enabled viral clearance from the nasal passages and lungs within two to four days. 

Sanofi’s recombinant technology and GSK’s pandemic adjuvant have shown past success in protecting against influenza. 

“Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile,” said Roger Connor, president of GSK Vaccines in a statement. 

In October, the two companies signaled their intent to provide 20 million vaccine doses to the COVAX Alliance,  

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
Johnson & Johnson vaccine trial results expected soon
OncoSec eyes next steps with its cancer immunotherapy candidate
Pharma researcher charged with theft of trade secrets  
Norway investigating deaths of 23 individuals who received COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards